TerminatedPhase 2

REGN5381 in Adult Participants With Uncontrolled Hypertension

Stopped: Sponsor decision

United Kingdom34 participantsStarted 2025-04-16

Plain-language summary

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs). The aim of the study is to see how effective the study drug is in reducing blood pressure. The study is designed as a 2-part study with participants initially enrolling in Part A. Part B of the study will commence and enroll the remaining study participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Who can participate

Age range30 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults with SBP ≥130 mm Hg and SBP ≤180 mm Hg at both screening and randomization visit, as described in the protocol
✓. ≥ 40 and ≤85 years on a stable regimen of ≥1 anti-hypertensive therapy for at least 1 month at the time of screening or ≥30 and \<40 years on a stable regimen of ≥3 anti-hypertensive therapies for at least 1 month at the time of screening

Exclusion criteria

✕. Heart rate \>100 bpm as described in the protocol
✕. Body mass index \>45 kg/m2 as described in the protocol
✕. Glomerular filtration rate (GFR) \<30 mL/min/1.73m2 at screening as described in the protocol
✕. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≥3x upper limit of normal (ULN) as described in the protocol

What they're measuring

Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP)

Timeframe: At week 12

Trial details

NCT IDNCT06833190

SponsorRegeneron Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-15

View on ClinicalTrials.gov More Uncontrolled Hypertension trials